MCL patient sample collection and its clinical parameters
| MCL sample no. . | Type . | Status . | Prior therapy . | CD19+ cells, % . | ROR1+ cells, %* . | GeoMean ratio† . |
|---|---|---|---|---|---|---|
| 1 | Classic | Relapse | Hyper-CVAD | 80 | 80 | 30 |
| 2 | Classic | Diagnosis | 74 | 95 | 29 | |
| 3 | Classic | Diagnosis | 86 | 79 | 14 | |
| 4 | Indolent | Diagnosis | 95 | 83 | 18 | |
| 5 | Classic | Diagnosis | 85 | 96 | 27 | |
| 6 | Classic | Relapse | Ibrutinib | 78 | 0 | 1 |
| 7 | Classic | Diagnosis | 69 | 93 | 7 | |
| 8 | Indolent | Diagnosis | 90 | 1 | 1 | |
| 9 | Blastoid | Relapse | R-CHOP | 85 | 99 | 22 |
| 10 | Indolent | Relapse | R-Fludarabine | 95 | 97 | 51 |
| 11 | Classic | Relapse | ND | 95 | 20 | 31 |
| 12 | Classic | Relapse | ND | 71 | 99 | 32 |
| 13 | Indolent | Relapse | R-CHOP | 95 | 97 | 8 |
| 14 | Classic | Diagnosis | 80 | 100 | 45 | |
| 15 | Blastoid | Relapse | R-CHOP | 90 | 20 | 7 |
| 16 | Indolent | Relapse | R-Benda | 85 | 99 | 17 |
| 17 | Classic | Relapse | ND | 80 | 97 | 12 |
| 18 | Indolent | Diagnosis | 68 | 95 | 10 | |
| 19 | ND | ND | ND | 85 | 98 | 20 |
| 20 | Classic | Diagnosis | 98 | 83 | 6 | |
| 21 | Classic | Diagnosis | 91 | 87 | 7 |
| MCL sample no. . | Type . | Status . | Prior therapy . | CD19+ cells, % . | ROR1+ cells, %* . | GeoMean ratio† . |
|---|---|---|---|---|---|---|
| 1 | Classic | Relapse | Hyper-CVAD | 80 | 80 | 30 |
| 2 | Classic | Diagnosis | 74 | 95 | 29 | |
| 3 | Classic | Diagnosis | 86 | 79 | 14 | |
| 4 | Indolent | Diagnosis | 95 | 83 | 18 | |
| 5 | Classic | Diagnosis | 85 | 96 | 27 | |
| 6 | Classic | Relapse | Ibrutinib | 78 | 0 | 1 |
| 7 | Classic | Diagnosis | 69 | 93 | 7 | |
| 8 | Indolent | Diagnosis | 90 | 1 | 1 | |
| 9 | Blastoid | Relapse | R-CHOP | 85 | 99 | 22 |
| 10 | Indolent | Relapse | R-Fludarabine | 95 | 97 | 51 |
| 11 | Classic | Relapse | ND | 95 | 20 | 31 |
| 12 | Classic | Relapse | ND | 71 | 99 | 32 |
| 13 | Indolent | Relapse | R-CHOP | 95 | 97 | 8 |
| 14 | Classic | Diagnosis | 80 | 100 | 45 | |
| 15 | Blastoid | Relapse | R-CHOP | 90 | 20 | 7 |
| 16 | Indolent | Relapse | R-Benda | 85 | 99 | 17 |
| 17 | Classic | Relapse | ND | 80 | 97 | 12 |
| 18 | Indolent | Diagnosis | 68 | 95 | 10 | |
| 19 | ND | ND | ND | 85 | 98 | 20 |
| 20 | Classic | Diagnosis | 98 | 83 | 6 | |
| 21 | Classic | Diagnosis | 91 | 87 | 7 |
Hyper-CVAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone; ND, not determined; R-Benda, rituximab and bendamustine; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-Fludarabine, rituximab and fludarabine.
From CD19+ cells.
Ratio of ROR1 GeoMean/control GeoMean.